Literature DB >> 28713159

Co-delivery of docetaxel and silibinin using pH-sensitive micelles improves therapy of metastatic breast cancer.

Xin-Yue Dong1, Tian-Qun Lang2, Qi Yin2, Peng-Cheng Zhang2, Ya-Ping Li2.   

Abstract

Breast cancer is the most vicious killer for women, and tumor metastasis is one of the leading causes of breast cancer therapy failure. In this study, a new pH-sensitive polymer (polyethylene glycol-block-poly[(1,4-butanediol)-diacrylate-β-N,N-diisopropylethylenediamine], BDP) was synthesized. Based on BDP, docetaxel/silibinin co-delivery micelles (DSMs) was constructed. DSM had a well-defined spherical shape under the transmission electron microscope with average hydrodynamic diameter of 85.3±0.4 nm, and were stable in the bloodstream but could dissociate to release the chemotherapeutic agents in the low pH environment of the endo/lysosomes in the tumor cells. Compared with free drugs, DSM displayed greatly enhanced cellular uptake, higher cytotoxicity and a stronger anti-metastasis effect against mouse breast cancer cell line 4T1. In 4T1 tumor-bearing mice treated with DSM (twice a week for 3 weeks), the inhibition rate on tumor growth and metastasis reached 71.9% and 80.1%, respectively. These results reveal that DSM might be a promising drug delivery system for metastatic breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28713159      PMCID: PMC5719157          DOI: 10.1038/aps.2017.74

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  26 in total

Review 1.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.

Authors:  Christian F Jehn; Philipp Hemmati; Silvia Lehenbauer-Dehm; Sherko Kümmel; Bernd Flath; Peter Schmid
Journal:  Clin Breast Cancer       Date:  2016-06-14       Impact factor: 3.225

Review 3.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

4.  Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy.

Authors:  Hai Wang; Yan Wu; Ruifang Zhao; Guangjun Nie
Journal:  Adv Mater       Date:  2013-01-22       Impact factor: 30.849

Review 5.  Proteomic applications for the early detection of cancer.

Authors:  Julia D Wulfkuhle; Lance A Liotta; Emanuel F Petricoin
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

6.  In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.

Authors:  Dhanya Nambiar; Vandana Prajapati; Rajesh Agarwal; Rana P Singh
Journal:  Cancer Lett       Date:  2012-09-26       Impact factor: 8.679

Review 7.  Strategies for the discovery and development of therapies for metastatic breast cancer.

Authors:  Bedrich L Eckhardt; Prudence A Francis; Belinda S Parker; Robin L Anderson
Journal:  Nat Rev Drug Discov       Date:  2012-06-01       Impact factor: 84.694

8.  Delivery of acetylthevetin B, an antitumor cardiac glycoside, using polymeric micelles for enhanced therapeutic efficacy against lung cancer cells.

Authors:  Jing-Jing Zhu; Xin-Xin Zhang; Yun-Qiu Miao; Shu-Fang He; Dan-Mei Tian; Xin-Sheng Yao; Jin-Shan Tang; Yong Gan
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

9.  Silibinin and indocyanine green-loaded nanoparticles inhibit the growth and metastasis of mammalian breast cancer cells in vitro.

Authors:  Hui-Ping Sun; Jing-Han Su; Qing-Shuo Meng; Qi Yin; Zhi-Wen Zhang; Hai-Jun Yu; Peng-Cheng Zhang; Si-Ling Wang; Ya-Ping Li
Journal:  Acta Pharmacol Sin       Date:  2016-05-02       Impact factor: 6.150

10.  Genes that mediate breast cancer metastasis to the brain.

Authors:  Paula D Bos; Xiang H-F Zhang; Cristina Nadal; Weiping Shu; Roger R Gomis; Don X Nguyen; Andy J Minn; Marc J van de Vijver; William L Gerald; John A Foekens; Joan Massagué
Journal:  Nature       Date:  2009-05-06       Impact factor: 49.962

View more
  4 in total

1.  Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.

Authors:  Bing-Bing Zhang; Xiao-Jie Chen; Xu-Dong Fan; Jing-Jing Zhu; Ying-Hui Wei; Hang-Sheng Zheng; Hong-Yue Zheng; Bin-Hui Wang; Ji-Gang Piao; Fan-Zhu Li
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

2.  Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis.

Authors:  Ying Liu; Xingmei Xie; Xuefeng Hou; Junyi Shen; Jiangpei Shi; Haizhen Chen; Yuanzhi He; Zhi Wang; Nianping Feng
Journal:  J Nanobiotechnology       Date:  2020-05-30       Impact factor: 10.435

Review 3.  Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.

Authors:  Vrinda Gote; Anantha Ram Nookala; Pradeep Kumar Bolla; Dhananjay Pal
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

4.  Breast Tumor-Derived Exosomal MicroRNA-200b-3p Promotes Specific Organ Metastasis Through Regulating CCL2 Expression in Lung Epithelial Cells.

Authors:  Pengfei Gu; Mayu Sun; Lei Li; Yang Yang; Zheshun Jiang; Yang Ge; Wenbo Wang; Wei Mu; Hui Wang
Journal:  Front Cell Dev Biol       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.